Market Cap | 265.60M | P/E | - | EPS this Y | 72.40% | Ern Qtrly Grth | - |
Income | -61.5M | Forward P/E | - | EPS next Y | 6.30% | 50D Avg Chg | -25.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -10.00% |
Dividend | N/A | Price/Book | EPS next 5Y | - | 52W High Chg | -53.00% | |
Recommedations | 1.70 | Quick Ratio | 5.53 | Shares Outst. | 216.07M | 52W Low Chg | 146.00% |
Insider Own | 10.79% | ROA | -58.07% | Shares Float | 180.50M | Beta | -0.20 |
Inst Own | 26.42% | ROE | -545.95% | Short Shares | 0 | Price | 1.06 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 8,146,296 | Target Price | 4.60 |
Oper. Margin | - | Earnings | Aug 12 | Volume | 2,729,526 | Change | -3.64% |
9 Meters Biopharma, Inc., a gastrointestinal platform company, focuses on patients with rare disorders and unmet needs. The company's pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease. It is developing NM-002, a long-acting injectable GLP-1 analogue for SBS; Larazotide, a Phase 3-stage therapeutic in development for celiac disease; and NM-003, a long-acting GLP-2 analogue, which is under orphan indication selection. 9 Meters Biopharma, Inc. is based in Raleigh, North Carolina.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own |
---|---|---|---|---|---|---|---|
Sirgo Mark A | Director Director | Sep 14, 8:06 AM | Buy | 0.64 | 148,485 | 95,030 | 21,485 |